RhoVac presents 3-year follow-up results of the phase I/II study in prostate cancer
RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company, announces today on October 5, 2021, that it has received and validated the top line results from its 3-year follow-up of the patients who took part in its phase I/II study that was concluded in 2018. The top-line results shows that the vast majority of patients still had undetectable PSA. Furthermore, the RhoC specific immune response has so far been assessed in 15 patients, and in these all but one patient who was a responder in the 1-year follow-up, still had RhoC specific immunity after 3 years. This exceeded expectations.A 3-